Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-36

So this is my anecdotal opinion.

There was a video recently recommended in the board; interview with Yuman Fong. In it he shows his preference to go with smaller players when partnering for research because big pharma has like a gazillion other higher priority things than to spend time with a small player like IMU trying to prove itself.

Perhaps IMU in general has this as a general strategy until they can get enough reputation generally. It makes sense, a smaller partner Precision Biosciences will want to make this work as well.